Clinical trials are research studies in which new treatments are tested against current standard treatments. They involve patients taking new drugs or undergoing new treatments to see whether these are effective in combating disease.
There are numerous breast cancer clinical trials currently underway throughout New Zealand and the rest of the world. These aim to identify new and more effective ways of treating breast cancer or ways of preventing it from occurring.
On this page you can find out more about how clinical trials work and the clinical trials that are currently underway in New Zealand. To find out more about the latest international research, check out our research news.
How does a clinical trial work?
Research nurse Jenni Scarlet tells us more about clinical trials,the different types of trials, reasons for participating and trial protocols.
Why participate in a clinical trial?
Breast cancer survivor Raewyn Calvert has been involved in a cinical trial and talks about reasons to participate in breast cancer research.
Breast Cancer Trials
Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand. The group has been conducting clinical trials research for the treatment and prevention of breast cancer in Australia and New Zealand for 40 years. Find out more about some of the ground-breaking outcomes of their research.
Current Clinical Trials
This clinical trial aims to find out if a new drug, ipatasertib, can slow the growth of advanced ER-positive, HER2-negative breast cancer when added to standard therapy (fulvestrant). New Zealand sites for this trial are: Auckland City Hospital and Wellington Hospital.
This clinical trial is investigating the efficacy and safety of adjuvant atezolizumab (Tecentriq) or placebo and trastuzumab emtansine (Kadcyla) for HER2-positive breast cancer at high risk of recurrence following preoperative therapy. New Zealand sites for this trials are: Auckland City Hospital and Tauranga Hospital.
This clinical trial compares the order of treatments for women who have oestrogen and/or progesterone receptor positive breast cancer and need both radiation treatment and hormone medication (anastrozole) to control the breast cancer following surgery. In New Zealand the trial is open in Auckland, Palmerston North and Christchurch.
This study will evaluate the efficacy and safety of GDC-0077 in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer. New Zealand sites for this trial are: Auckland City Hospital, Waikato Hospital, Palmerston North Hospital and Christchurch Hospital.
This clinical trial is investigating the efficacy and safety of GDC-9545 combined with palbociclib compared with Letrolzole combined with palbociclib in patients with oestrogen receptor positive, HER2-negative, locally advanced or metastatic breast cancer. New Zealand sites for this trial are Auckland City Hospital and Waikato Hospital.
POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes.
This is a randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A early breast cancer. The purpose of this study is to see whether a specialised laboratory test (Prosigna (PAM50) Assay) of breast cancer tissue can be used to choose women who can safely avoid radiation therapy because there is a low risk of the cancer coming back. New Zealand sites are Waikato Hospital, Christchurch Hospital, Wellington Hospital and Palmerston North Hospital.
This phase II, pragmatic, randomised controlled trial will compare lymph node grafting, in addition to standard lymphoedema therapy; against standard lymphoedema therapy alone. Study participants will be those with residual stage one to two breast-cancer related lymphoedema, despite initial treatment with standard lymphoedema therapy.
This is a randomised, open label, Phase III Trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer. It is open to people diagnosed with hormone receptor (HR) positive, Human Epidermal Growth Factor Receptor 2 (HER-2) positive metastatic breast cancer.
The NeoN trial is coordinated through Breast Cancer Trials and investigates if using an immunotherapy drug alone prior to the combination of immunotherapy and standard chemotherapy is safe and effective in treating breast cancer before surgery. This trial was open to both women and men diagnosed with unilateral triple negative early breast cancer.
A randomised, open label, Phase III study of abemaciclib combined with standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, HER2 negative breast cancer. The aim of this study, MonarchE, is to evaluate whether the combination of abemaciclib plus standard adjuvant endocrine therapy improves outcomes in participants with a certain type of breast cancer compared to adjuvant endocrine therapy alone. This study is now closed; no new patients will be recruited but those already in the study will continue to be followed up. Results published so far have shown that adding abemaciclib to endocrine therapy significantly reduces the risk of recurrence in these patients.
Suppression of Ovarian Function Trial. A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer. New Zealand sites are Waikato Hospital, Christchurch Hospital, Palmerston North Hospital and Auckland Hospital.
This trial, which began in 2006, has compared two operations for detecting cancer cells in the lymph nodes of women with early breast cancer - sentinal node biopsy versus auxillary clearance. It followed on from an earlier trial, SNAC-1, and aimed to extend its findings by recruiting women with larger tumours and multiple tumours. A fact sheet about the SNAC trials can be seen here. SNAC-2 follow-up was completed in January 2023 and analysis of the results is currently under way.
This trial was for women who have ductal carcinoma in situ (DCIS) of the breast. It aimed to see whether improvements could be made to radiation treatment after surgery by giving women an extra treatment 'boost' dose, and also whether a shorter course of whole breast irradiation was as effective as a long one. In a recent study summary, the researchers concluded that the boost treatment reduced the risk of recurrence and that the shorter course of whole breast irradiation (16 treatments) was as effective as the longer course. A final analysis of all results is planned for 2024.
This trial investigated whether an adapted Mediterranean diet improves health outcomes for women who have been treated for early stage breast cancer. Study participants were divided into three groups: one group followed an adapted Mediterranean diet, another followed a low-fat diet, and the third (control) group ate their normal diet. Compared to the control group, both the 'diet' groups lost weight, with significant decreases in body mass index (BMI) and waist circumference, and had improved blood biomarkers, such as blood lipids and blood glucose. Both diet groups showed satisfactory adherence to their diets. The researchers concluded that nutritional education and group support appears to exert beneficial effects on health in breast cancer survivors; of lesser importance is the type of diet that forms the basis of the education.
The pubished results of this study can be seen here.
The PantoCIN trial aimed to test the ability of a cheap, widely available drug to prevent two of chemotherapy's most unpleasant side-effects: delayed nausea and vomiting. These can occur after breast cancer chemotherapy, affecting the quality of life. A potential cause of these delayed side effects is that the chemotherapy may cause stomach irritation. Pantoprazole is commonly used to treat stomach irritation by reducing stomach acid, which may, in turn, improve nausea and/or vomiting. This study has explored whether this medication can help prevent these side effects from chemotherapy for early breast cancer. This trial has now been completed and has shown that pantoprazole is an effective treatment. Find out more.
QUE Oncology has completed a Phase II trial at several sites in New Zealand for its novel non-hormonal therapy for women with breast cancer suffering hot flushes and night sweats. After a breast cancer diagnosis, women are routinely prescribed drugs such as tamoxifen or aromatase inhibitors (known as endocrine therapy) for up to 10 years post-diagnosis. These drugs are known to reduce the recurrence of breast cancer by reducing or blocking the action of estrogen, a hormone known to stimulate the growth of breast cancer. However, the most common side-effect of reducing estrogen is an increased likelihood of hot flushes and night sweats. These symptoms can severely impact a woman's quality of life and often cause them to stop taking their breast cancer treatment. QUE Oncology is looking to develop a therapy to address these symptoms. Find out more about the trial here.
The final results of MARIANNE were published in 2019. They showed that trastuzumab emtansine (T-DM1) with or without pertuzumab showed noninferior progression-free survival and better tolerability than trastuzumab plus a taxane for the treatment of HER2-positive advanced breast cancer. The researchers concluded that the results supported the use of trastuzumab emtansine as a first-line treatment for patients with HER2-positive metastatic breast cancer who are deemed unsuitable for taxane-based therapy.